Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“American Society of Clinical Oncology (ASCO) 2026 is 5 weeks away.
Here are the 10 lung cancer trials I’m watching most closely and why each one matters.
From the first real challenge to chemotherapy in EGFR exon 20 insertions, to 7 years of CROWN follow-up, to the first dedicated trial in STK11/KEAP1/KRAS-mutant NSCLC, this is one of the strongest lung cancer programs American Society of Clinical Oncology (ASCO).
What stood out: TRITON finally asks the right question in the patients who respond least to IO. That’s the session I’ll be in my seat for.”
Other articles featuring Aakash Desai.